OUR IMMUNO-ONCOLOGY CLINICAL PIPELINE

Nektar Therapeutics is developing novel immunotherapies that harness key steps in the cancer immunity cycle1

Other cancersGenitourinary cancers

Advanced renal cell carcinoma

BEMPEG +NIVO

Muscle-invasive bladder cancer

BEMPEG + NIVO

Advanced bladder cancer

BEMPEG + NIVO

Advanced renal cell carcinoma

BEMPEG + NIVO + axitinib

Advanced melanoma

BEMPEG +NIVO

Adjuvant melanoma

BEMPEG + NIVO

Head and neck SCC

BEMPEG + Pfizer compounds

Metastatic prostate cancer

BEMPEG + Pfizer compounds

Advanced NSCLC

BEMPEG + pembrolizumab

Head and neck SCC

BEMPEG + VB10.NEO

Advanced solid tumors

NKTR-262 + BEMPEG

R/R NHL or multiple myeloma

NKTR-255 (IL-15RA)

PreclinicalProgramIndicationPartner Phase 1 Phase 2 Phase 3

BEMPEG, bempegaldesleukin (NKTR-214); FDA, U.S. Food and Drug Administration; IL-15RA, interleukin-15 receptor agonist; NHL, non-Hodgkin lymphoma; NIVO, nivolumab; NSCLC, non-small cell lung cancer; R/R, relapsed/refractory; SCC, squamous cell carcinoma.

1. Chen DS, Mellman I. Immunity 2013;39:1–10.

NCT03635983

NCT04052204

NCT04052204

NCT03138889

NCT03548467

NCT03435640

NCT04136756

NCT04410445

NCT03729245

NCT04209114

FDA Accelerated Approval registrational studyNCT03785925

NCT04540705

SCAN HERE to discover more about BEMPEG at Nektar.com

or email medicalaffairs@nektar.com

Registrational study

Registrational study

Registrational study

Registrational study

THE CANCER IMMUNITY CYCLE

Infiltration of T cells into tumor

Recognition of cancer cells by T cells

Killing of cancer cells

Priming, proliferation, activation

Release of cancer cell antigens

Cancer antigen presentation

Primes, proliferates, activates, and increases tumor-infiltrating lymphocytes;

increases PD-1 expression

BEMPEG (CD122-preferential agonist)5,6

Activates dendritic cell responseNKTR-262 (TLR 7/8 agonist)2–4

Key processes in the cancer immunity cycle must be activated, engaged, and promoted for an anticancer immune response to lead to the effective killing of cancer cells1

FOR EDUCATIONAL PURPOSES ONLY.These compounds and the combinations of agents and their uses have not been approved.

Nektar Therapeutics, 455 Mission Bay Boulevard South, San Francisco, California 94158. Copyright Nektar Therapeutics © 2020. All rights reserved.

BEMPEG, bempegaldesleukin (NKTR-214); IL, interleukin; NK, natural killer; PD-1, programmed death-1; TLR, toll-like receptor.

1. Chen DS, Mellman I. Immunity 2013;39:1–10. 2. Adams S. Immunotherapy 2009;1:949–964. 3. Kivimae S, et al. J Immunother Cancer 2017;5(Suppl 2):P275. 4. Lee M. Cancer Res 2018;78(13 Suppl):2755. 5. Charych DH, et al. Clin Cancer Res 2016;22:680–690. 6. Diab A, et al. J Immunother Cancer 2019;7(Suppl 1):O35. 7. Miyazaki T, et al. Cancer Res 2019;79(Suppl):3265. 8. Chou CK, et al. HemaSphere 2019;3(Suppl):PS1208.

NK cell

Tumor cells

CD8+ T cell (effector memory)

CD8+ T cell (central memory)

Dendritic cell

Tumor antigen

Stimulates and expands NK cells; promotes survival and expansion

of memory CD8+ T cells

NKTR-255 (IL-15 receptor agonist)7,8

Small-molecule therapy Cytokine therapy (IL-2 and IL-15)